Recent advances in PKC inhibitor development: Structural design strategies and therapeutic applications

Area of Science:

• Biochemistry and Molecular Biology
• Medicinal Chemistry
• Drug Discovery

Background:

• Protein Kinase C (PKC) isozymes are crucial regulators of cellular functions, implicated in diseases such as cancer, diabetes, and autoimmune disorders.
• Despite decades of research, developing selective and effective PKC inhibitors for therapeutic use has been difficult, with only one approved drug.
• Targeting specific PKC isozymes, like PKCα and PKCβ, is critical for therapeutic efficacy.

Purpose of the Study:

• To review recent advancements in small-molecule Protein Kinase C (PKC) inhibitor development.
• To analyze novel structural design strategies, pharmacological activities, and structure-activity relationships.
• To highlight emerging approaches and challenges in creating selective PKC inhibitors for improved therapeutic potential.

Main Methods:

• Review of recent literature on small-molecule PKC inhibitors.
• Analysis of fragment-based drug design, allosteric targeting, and natural product derivatization.
• Examination of computational methods and structural biology insights in PKC inhibitor design.

Main Results:

• Emerging strategies like fragment-based design and allosteric targeting have generated promising new scaffold classes.
• Innovations in achieving isozyme selectivity, particularly for PKCα and PKCβ, are crucial for therapeutic applications.
• Integration of computational and structural data has advanced understanding of PKC inhibition mechanisms.

Conclusions:

• Significant challenges remain in PKC drug development, including achieving high selectivity and minimizing off-target effects.
• Promising future directions involve leveraging rational design principles for next-generation PKC inhibitors.
• The findings provide a framework for developing PKC inhibitors with enhanced clinical potential.